Skip to content
Optionomics Free · No account needed

Earnings analysis · 10-Q

PURE earnings analysis

Filed June 15, 2026 · Our reading of the company's report

The latest report

PURE Bioscience, Inc. reported a modest increase in revenue but faced significant challenges including a net loss and ongoing liquidity concerns. The company recorded revenues of $506,000 for the quarter ended April 30,…

Read full summary

PURE Bioscience, Inc. reported a modest increase in revenue but faced significant challenges including a net loss and ongoing liquidity concerns. The company recorded revenues of $506,000 for the quarter ended April 30, 2026, marking a slight year-over-year increase, while also struggling with rising costs and decreased gross margins.

Read the original on SEC.gov

Reported figures

Earnings per share
$-0.01
Gross margin
53%

What stood out

  • Revenue Growth Year-over-Year

    Net product sales rose to $506,000 in Q3 2026 from $489,000 in Q3 2025, up by $17,000.

  • Stable Gross Margin

    Gross margin percentage decreased slightly to 53% in Q3 2026 compared to 57% in Q3 2025 due to a change in product mix.

  • Decreased SG&A Expenses

    Selling, general and administrative expenses fell by $68,000 from $776,000 in Q3 2025 to $708,000 in Q3 2026.

  • Improved Cash Position

    Cash and cash equivalents rose to $983,000 as of April 30, 2026, up from $334,000 as of July 31, 2025.

  • Increased Interest Expense

    Interest expense was $106,000 in Q3 2026, compared to $78,000 in Q3 2025, due to accrued interest on convertible notes.

  • Management Changes

    CEO Robert Bartlett is set to retire on August 1, 2026, with Jeffrey Kitchell promoted to CEO.

What to watch

  • Liquidity Concerns

    As of April 30, 2026, the company has a stockholder deficiency of $5,839,000 and recurring losses totaling $1,873,000 this period.

  • Debt Servicing Costs

    Interest expense rose due to convertible notes; the company reported $301,000 in interest expense for the nine months ended April 30, 2026, up from $210,000 year-over-year.

  • Going Concern Doubts

    Negative cash flows from operations and ongoing losses raise substantial doubt about the company's ability to continue as a going concern.

Management's outlook

Management indicates severe liquidity constraints and the need for capital raises to fund operations, but avoids providing specific numeric guidance.

This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.